NewAmsterdam Pharma Company N.V. Company Profile
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 12:20 PM ET
NewAmsterdam Pharma N.V. at a glance
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Naarden, Netherlands. NewAmsterdam Pharma N.V. is led by Dr. Michael Harvey Davidson FACC, Facp., M.D. and employs about 100 people. At a market capitalization of $2.49 billion, it is considered a mid-cap company.
Its SEC Central Index Key (CIK) is 0001936258, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does NewAmsterdam Pharma N.V. do?
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Business description based on the company's public filings.
Company information
- Legal name
- NewAmsterdam Pharma Company N.V.
- Ticker
- NASDAQ: NAMS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Employees
- 100
- Headquarters
- Gooimeer 2-35, Naarden, Netherlands
- Phone
- 31 35 206 2971
- Website
- newamsterdampharma.com
- Market cap
- $2.49B
- SEC CIK
- 0001936258
- Latest annual report
- 10-K · Feb 18, 2026
Companies similar to NewAmsterdam Pharma N.V.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SUPNSupernus Pharmaceuticals Inc. | 42.99 | +2.02% | $2.50B | vs NAMS |
| LQDALiquidia Corporation | 28.04 | +0.07% | $2.51B | vs NAMS |
| HCMHUTCHMED (China) Limited ADR | 14.04 | +2.71% | $2.44B | vs NAMS |
| MBXMBX Biosciences Inc. | 52.60 | -1.23% | $2.53B | vs NAMS |
| IRONDisc Medicine Inc. | 62.78 | +3.31% | $2.41B | vs NAMS |
| NRIXNurix Therapeutics Inc. | 23.08 | +3.92% | $2.40B | vs NAMS |
| HRMYHarmony Biosciences Holdings Inc. | 40.36 | +1.92% | $2.35B | vs NAMS |
| SLSSELLAS Life Sciences Group Inc. | 11.63 | +3.24% | $2.35B | vs NAMS |